To include your compound in the COVID-19 Resource Center, submit it here.

J&J submits Xarelto responses

Johnson & Johnson (NYSE:JNJ) submitted a response to an FDA complete response letter for an sNDA for Xarelto rivaroxaban to reduce the risk

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE